Anthera Pharmaceuticals (NASDAQ:ANTH) was downgraded by equities researchers at Piper Jaffray Companies from an “overweight” rating to an “underweight” rating in a note issued to investors on Monday, The Fly reports.
A number of other analysts also recently issued reports on ANTH. HC Wainwright reissued a “buy” rating on shares of Anthera Pharmaceuticals in a research report on Tuesday, March 6th. ValuEngine raised Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, December 31st. Zacks Investment Research raised Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research report on Monday, February 5th. Finally, Roth Capital assumed coverage on Anthera Pharmaceuticals in a research report on Wednesday, February 21st. They issued a “buy” rating and a $10.00 target price for the company. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $4.38.
Anthera Pharmaceuticals (NASDAQ:ANTH) traded down $2.12 during trading hours on Monday, reaching $0.52. The company’s stock had a trading volume of 28,744,615 shares, compared to its average volume of 2,283,758. Anthera Pharmaceuticals has a twelve month low of $0.40 and a twelve month high of $5.60. The stock has a market capitalization of $36.56, a P/E ratio of -0.15 and a beta of 2.22.
A number of large investors have recently added to or reduced their stakes in ANTH. 683 Capital Management LLC purchased a new stake in Anthera Pharmaceuticals in the fourth quarter worth $399,000. Armistice Capital LLC purchased a new position in shares of Anthera Pharmaceuticals in the fourth quarter valued at $1,269,000. Finally, BVF Inc. IL grew its position in shares of Anthera Pharmaceuticals by 20.9% in the fourth quarter. BVF Inc. IL now owns 1,216,403 shares of the biopharmaceutical company’s stock valued at $2,007,000 after purchasing an additional 209,896 shares in the last quarter. 28.12% of the stock is owned by institutional investors and hedge funds.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.